NCT03383679View on ClinicalTrials.gov

Study on Androgen Receptor and Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 14, 2018

Primary Completion Date

November 30, 2021

Study Completion Date

July 20, 2022

Conditions
Breast Cancer FemaleTriple Negative and Androgen Receptor Positive
Interventions
DRUG

Darolutamide

treatment with darolutamide

DRUG

Capecitabine

treatment with capecitabine

Trial Locations (1)

14000

Centre François Baclesse, Caen

All Listed Sponsors
lead

UNICANCER

OTHER

NCT03383679 - Study on Androgen Receptor and Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter